Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack®
model DF-F non-invasive blood glucose measurement device, announced that
Avner Gal, the Company’s Chief Executive Officer, will present at the
AMIZINO Fall 2013 Small Cap/Micro Cap Investment Conference at 9:00 a.m.
PT on Tuesday, October 29, 2013. The conference will be held at the
Sheraton Seattle Hotel, 1400 Sixth Avenue, Seattle, Washington.
In his presentation, Mr. Gal will discuss the Company’s CE Marked
GlucoTrack® model DF-F non-invasive glucose monitoring
device, designed for spot measuring. GlucoTrack aims to help people with
diabetes obtain blood glucose level measurements without the pain,
inconvenience, incremental cost and difficulty of conventional spot
finger stick devices.
About the AMIZINO Fall 2013 Small Cap/Micro Cap Investment Conference
This conference is a collaboration between Accredited Members, Inc., a
membership-based financial research firm specializing in small cap/micro
cap research that hosts 3-4 investment conferences annually, and ZINO
Society, a premier membership, business and social network that connects
accredited investors with entrepreneurs seeking funding.
About Integrity Applications, Inc.
Integrity Applications, Inc. is a medical device company focused on the
design, development and commercialization of non-invasive glucose
monitoring devices for use by people with diabetes. Integrity
Applications has developed the GlucoTrack model DF-F non-invasive
glucose monitoring device, which is designed to help people with
diabetes obtain blood glucose level measurements without the pain,
inconvenience, incremental cost, and difficulty of conventional
(invasive) spot finger stick devices. Integrity Applications works
primarily through its wholly-owned Israeli subsidiary, A.D. Integrity
Applications, Ltd. For more information please visit www.integrity-app.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Statements
contained in this news release that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting
the generality of the foregoing, words such as "will," and "believe,"
are intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect Integrity
Applications’ actual results and could cause such results to differ
materially from any forward-looking statements that may be made in this
news release. Factors that may affect Integrity Applications’ results
include, but are not limited to, the ability of Integrity applications
to successfully commercialize the GlucoTrack DF-F; the ability of the
GlucoTrack DF-F to achieve acceptable pricing, adequate third party
reimbursement or market acceptance; the ability of Integrity
Applications to manage its growth and the expansion of its operations to
include commercialization activities; risks relating to the use of third
party manufacturers; risks relating to the development of Integrity
Applications’ sales, marketing and distribution capability, either on
its own or through collaborations with marketing partners; and the
additional risk factors described in Integrity Applications’ filings
with the U.S. Securities and Exchange Commission, including its Annual
Report on Form 10-K for the year ended December 31, 2012.
Copyright Business Wire 2013